AC Garrido-Castro, NU Lin, K Polyak - Cancer discovery, 2019 - AACR
Triple-negative breast cancer (TNBC) remains the most challenging breast cancer subtype to treat. To date, therapies directed to specific molecular targets have rarely achieved …
Abstract The AURORA US Metastasis Project was established with the goal to identify molecular features associated with metastasis. We assayed 55 females with metastatic …
B Pal, Y Chen, F Vaillant, BD Capaldo, R Joyce… - The EMBO …, 2021 - embopress.org
To examine global changes in breast heterogeneity across different states, we determined the single‐cell transcriptomes of> 340,000 cells encompassing normal breast, preneoplastic …
S Ramón y Cajal, M Sesé, C Capdevila… - Journal of Molecular …, 2020 - Springer
In this review, we highlight the role of intratumoral heterogeneity, focusing on the clinical and biological ramifications this phenomenon poses. Intratumoral heterogeneity arises through …
Z Gong, Q Li, J Shi, P Li, L Hua, LD Shultz… - Science immunology, 2023 - science.org
Neutrophils, the most abundant innate immune cells, function as crucial regulators of the adaptive immune system in diverse pathological conditions, including metastatic cancer …
Z Gong, Q Li, J Shi, ET Liu, LD Shultz, G Ren - Cell metabolism, 2022 - cell.com
While the distant organ environment is known to support metastasis of primary tumors, its metabolic roles in this process remain underdetermined. Here, in breast cancer models, we …
Z Hu, Z Li, Z Ma, C Curtis - Nature genetics, 2020 - nature.com
Metastasis is the primary cause of cancer-related deaths, but the natural history, clonal evolution and impact of treatment are poorly understood. We analyzed whole-exome …
Metastasis has been considered as the terminal step of tumor progression. However, recent genomic studies suggest that many metastases are initiated by further spread of other …
E Vagia, D Mahalingam, M Cristofanilli - Cancers, 2020 - mdpi.com
Triple negative breast cancer (TNBC) constitutes the most aggressive molecular subtype among breast tumors. Despite progress on the underlying tumor biology, clinical outcomes …